IMM 1.72% 29.5¢ immutep limited

Yes, will be interesting to watch. Similar in CVac really only...

  1. 701 Posts.
    Yes, will be interesting to watch.
    Similar in CVac really only through the target, MUC-1.
    Stimuvax uses a liposomal delivery, CVac is personalised with autologous dendritic cells.
    Stimuvax isn't the one to watch from Oncothyreon, though. ONT-10 looks better in most respects except pipeline.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.